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ucleos(t)ide analogues. Patients were evaluated based on
irologic and serologic response to therapy, and were clas-
iﬁed as patients with a detectable level of HBV DNA and
ndetectable HBV DNA (<1.08 log copies/ml). The muta-
ions associated with HBV drug resistance were investigated
n patients with detectable HBV DNA. Due to resistance, in
his group of patients treatment was change.
Results: In our study group, four patients devel-
ped LAM-associated mutations (rtL180M+rtM204V,
tL180M+rtM204V/I, and 2 present rtM204I), three patients
eveloped ADV-associated mutations (rtA181V+rtN236T;
tN236T and rtA181V), one patient developed ADV+LAM
ssociated mutations (rtL180M+rtA181V+rtN236T) and
ther patient developed ETV-associated mutations
rtL180M+rtT184A+rtS202G+rtM204V). Beside the primary
esistant mutations, various combinations of secondary
nd compensatory mutations conferring resistance to
ucleos(t)ide analogues were detected in 5 (33%) patients.
Conclusion: HBV treatment with nucleoside analogues
esults in the development of mutants strains, leading
o drug resistance. These data suggest an early develop-
ent of ETV resistance in patients with prior LAM and ADV
esistance. Therefore genotypic resistance is important in
onitoring HBV treatment. In conclusion, optimization of
herapy combining LAM and ADV may be a good choice for
atients with hepatitis B who have resistance mutations to
DV or LMV.
oi:10.1016/j.ijid.2010.02.2008
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Background: Over the last few years a new concept
as intoduced a possibility a SVR may indicate cure. VHC-
RN clearence at 6 months after therapy discontinuation
VR (sustained virologic response) is generally assumed as
robable cure. The medical literature shows a signiﬁcative
eduction in the rate of progression to cirrosis and Hep-
tocarcinoma development in patients who achieved SVR
ompared to non responders and relapsers.
Methods: We retrospectively analysed a group of VHC
atients that fulﬁlled histologic criteria for antiviral treat-
ent from 1998 to 2009. We performed VHC ARN PCR
eterminations at baseline, during treatment, in the last
eek of antiviral treatment, every 6 months’ until the 2◦
ear after therapy discontinuation. and once a year further
n. We deﬁned ETR as negative or undetectable ARN VHC
CR in the last week of antiviral treatment.
Results: In our study 38 patients achieved ETR (nega-
ive VHC PCR during the ﬁnal week of IFN treatment). Only
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patients that achieved ETR showed early relapse in the
ext six months after stopping therapy (so they not achieved
VR). The rest of the patients are not detectable up to the
ast control., in the long term follow up.
Conclusion: In this small group of patients we didn‘t ﬁnd
elapses after 6 months following discontinuation of therapy,
ith a mean follow up of nearly 10 years The period of higest
isk of relapses was the next 12 months after the end of
reatment. The rate of relapses after 24 months of the end
f treatment was very low, as estimated in different studies
etween 1 and 2%.
oi:10.1016/j.ijid.2010.02.2009
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Background: The objectives were to estimate the preva-
ence of hepatitis A among children and adolescents from
outh and southeast region of Brazil and to identify
ndividual-, household- and area-levels factors associated
ith hepatitis A infection.
Methods: This population-based survey was conducted
n 2007—2008 and covered individuals aged between 5 and
9 years. A stratiﬁed multistage cluster sampling technique
ith probability proportional to size was used to select
.054 individuals aged between 5 and 19 years living in
he State capitals of 7 states in the study regions. The
ample was stratiﬁed according to age (5—9 and 10- to
9-years-old) and capital within each region. Individual-
nd household-level data were collected by interview at
he home of the individual. Variables related to the area
ere retrieved from census tract data. The outcome was
otal antibodies to hepatitis A virus detected using com-
ercial EIA. The associations between HAV infection and
ndependent variables were assessed using the odds ratio
nd corrected for the random design effect and sampling
eight. Multilevel analysis was performed by GLLAMM using
tata 9.2.
Results: The prevalence of hepatitis A infection in the
—9 and 10—19 age-group was 20,6 and 37,7%, respec-
ively for the Southeast and, 18,9 and 34,5%, respectively
or the South. A trend for the prevalence of HAV infec-
ion to increase according to age was detected in all sites.
ultilevel modeling showed that variables relating to differ-
nt levels of education were associated with HAV infection
n all sites. The multilevel model showed that individual,
ousehold- and area-level variables are independently asso-
iated with HAV infection. Age is an important predictor of
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outcome. Additionally, education and sewage disposal ser-
vice variables that were collected through household-level
interviews or retrieved from IBGE census tract data were
associated with HAV infection in all sites.
Conclusion: The study sites were classiﬁed as areas with
low endemicity area for hepatitis A infection. This multilevel
model allowed for quantiﬁcation of contextual predictors of
hepatitis A infection in urban areas.
doi:10.1016/j.ijid.2010.02.2010
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Background: In 1989, the Brazilian government ﬁrst
implemented immunization against hepatitis B for infants
and children in the western Amazon region and gradually
expanded this to other regions. Vaccination of risk groups
for the whole country started in 1992, and new groups have
been successively added to the original list. Since 1998,
the HBV vaccine has been incorporated into the immuniza-
tion schedule for infants as a national policy and, in 2001,
this was broadened to include children and adolescents.
Ppopulation-based survey was conducted in Brazil to esti-
mate the prevalence of and risk factors for HBV infection
from South and Southeast region of Brazil.
Methods: Random multistage cluster sampling was used
to select individuals aged 13-69 years. Outcomes indicat-
ing HBV infection were anti-HBc and HBsAg. HBsAg-positive
samples were tested for HBV-DNA and genotyped. Univariate
and multivariate analyses were performed.
Results: Overall, 10.496 individuals were included; the
prevalence of anti-HBc was: South 1,58% for 10—19 and 11,3
for 20—69 years old; Southeast 0,61% for 10—19 and 7,9 for
20—69 years old. HBsAg positivity was less than 0,5% in all
areas. Genotypes 3A, 1b,1a and 2b were identiﬁed. Age were
associate with HBV infection in all region and male were
independently associated with HBV infection in Southeast.
Conclusion: Our survey classiﬁed the South and Southeast
region of Brazil as low HBV endemicity areas. Our ﬁndings
that age is risk factors for HBV reinforce the need for exten-
sive HBV vaccine coverage among adolescents to prevent
viral infection. All individuals belonging to the risk groups
identiﬁed by our survey should be considered candidates for
HBV vaccine and educational measures. Therefore, vaccina-
tion upon request for individuals without speciﬁc risk should
be considered, in accordance with the current CDC recom-
mendations. This survey shows the importance of generating
r
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opulation-based information to facilitate comprehensive
accination and of developing educational strategies that
ddress regional differences.
oi:10.1016/j.ijid.2010.02.2011
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Background: Hepatitis A is an acute, usually self-limiting
isease of the liver, caused by hepatitis A virus. Patients
ith chronic liver disease are at increased risk of severe
omplications, related to hepatitis A, which, in some
ircumstances, may even lead to death. Therefore, it
s postulated that HAV susceptible individuals (anti-HAV
eronegative subjects) should be vaccinated against HAV to
revent or diminish morbidity and mortality of the disease.
im: Evaluation of the prevalence of anti-HAV antibodies
mong patients in different age groups with chronic hepati-
is C.
Methods: 133 patients (the mean age: 38.3 yrs) with CHC
ere divided into two groups, according to age (Table 1).
he control group consisted of 150 healthy young medical
tudents (the mean age: 25.3 yrs). The presence of anti-
AV and addition of HBV infection viral markers: anti HBc
nd HBsAg in blood sera of the patients and of the control
roup were assessed, using the standard EIA method (Cobas
oche).
Results: The prevalence of anti HAV antibodies and HBV
nfectionmarkers among the evaluated groups are presented
n Table 1.
roup Age
years
Pt n anti HAV Anti-HBc HBsAg
n % n % n %
HC 18—30 33 5 15.5 6 18.8 0 0
31—73 100 47 47.0 27 27.0 2 2
ontrol
24—26
150 15 10.0 8 5.3 2 1.33
In the study groups, age-dependent, differentiated
revalence of anti-HAV and anti-HBc was observed among
ounger (< 31 years) and older (> 30 years) patients with CHC
15.5% vs. 47.0%; p = 0.05 and 18.8% vs. 27%, p = 0.05, respec-
ively), which was higher than in healthy controls (10.0% and
.3%, respectively).
Conclusion: Patients below 31 with CHC present signif-
cantly lower anti-HAV and anti-HBc prevalence than older
nes, what creates a substantial risk for fulminant liver fail-
re and even death in case of HAV or HBV infection. Thus
accination programmes against HAV and HBV are strongly
ecommended in these groups of patients.
oi:10.1016/j.ijid.2010.02.2012
